¼¼°èÀÇ ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå
Whole Genome Sequencing
»óǰÄÚµå : 1773949
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 464 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,239,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,719,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

ÀüÀå À¯Àüü ½ÃÄö½Ì ¼¼°è ½ÃÀåÀº 2030³â±îÁö 58¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 21¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÀüÀå À¯Àüü ½ÃÄö½Ì ¼¼°è ½ÃÀåÀº 2024³âºÎÅÍ 2030³â±îÁö CAGR 19.0%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 58¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ±â±â´Â CAGR 16.6%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 28¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼Ò¸ðǰ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 22.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 5¾ï 6,030¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 25.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀåÀº 2024³â¿¡´Â 5¾ï 6,030¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 13¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 25.3%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, °¢°¢ ºÐ¼® ±â°£ µ¿¾È¿¡ 15.4%¿Í 16.8%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 15.8%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Àü ¼¼°è ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

ÀüÀå À¯Àüü ½ÃÄö½ÌÀÌ À¯ÀüüÇÐ ºÐ¾ß¸¦ º¯È­½ÃŰ´Â ÀÌÀ¯´Â?

ÀüÀå À¯Àüü ½ÃÄö½Ì(WGS)Àº °³ÀÎÀÇ Àüü À¯ÀüÀÚ Äڵ忡 ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÔÀ¸·Î½á À¯ÀüÀÚ ¿¬±¸, Áø´Ü ¹× ¸ÂÃãÇü ÀÇ·á¿¡ Çõ¸íÀ» ÀÏÀ¸Ä×½À´Ï´Ù. ƯÁ¤ À¯ÀüÀÚ¿¡ ÃÊÁ¡À» ¸ÂÃá Ç¥Àû ¿°±â¼­¿­ ºÐ¼®°ú ´Þ¸®, WGS´Â »ý¹°Ã¼ ³»ÀÇ ¸ðµç DNA ¿°±â¼­¿­À» Á¶»çÇÏ¿© À¯ÀüÀû º¯ÀÌ, Áúº´ À§Çè, ÁøÈ­Àû ÇüÁú¿¡ ´ëÇÑ ´õ ±íÀº ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. À¯Àü¼º Áúȯ, Èñ±Í Áúȯ, ¾ÏÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ÀÇ·á ¼­ºñ½º Á¦°øÀÚ°¡ º¸´Ù Á¤È®ÇÏ°í ¸ÂÃãÈ­µÈ Ä¡·á Á¢±Ù¹ýÀ» ¿ä±¸ÇÔ¿¡ µû¶ó ÀÓ»ó Áø´Ü¿¡¼­ WGS¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾à¹°À¯ÀüüÇÐ ºÐ¾ß¿¡¼­´Â WGS¸¦ Ȱ¿ëÇÏ¿© °³ÀÎÀÇ À¯ÀüÀû üÁú¿¡ µû¶ó ¾à¹° ó¹æÀ» Á¶Á¤ÇÏ¿© ºÎÀÛ¿ëÀ» ÁÙÀ̰í Ä¡·á È¿°ú¸¦ Çâ»ó½Ã۰í ÀÖ½À´Ï´Ù. ³ó¾÷, ¹Ì»ý¹°ÇÐ, ¹ýÀÇÇп¡¼­ÀÇ À¯Àüü µ¥ÀÌÅÍ È°¿ë È®´ëµµ WGSÀÇ Àû¿ë ¹üÀ§¸¦ ³ÐÈ÷°í ÀÖ½À´Ï´Ù. ½ÃÄö½Ì ºñ¿ëÀÌ Áö¼ÓÀûÀ¸·Î °¨¼ÒÇϰí À¯Àüü ºÐ¼®À» À§ÇÑ °è»ê µµ±¸°¡ °³¼±µÊ¿¡ µû¶ó WGS´Â ÀÇÇÐ ¹× °úÇÐ ¿¬±¸ÀÇ ÁÖ·ù µµ±¸°¡ µÇ¾î Á¤¹Ð ÀÇÇÐÀÇ È¹±âÀûÀÎ ¹ßÀüÀ» À§ÇÑ ±æÀ» ¿­¾î°¡°í ÀÖ½À´Ï´Ù.

AI¿Í Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀº ¾î¶»°Ô ÀüÀå À¯Àüü ¼­¿­À» °­È­ÇÒ ¼ö ÀÖÀ»±î?

ÀΰøÁö´É(AI)°ú Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀÇ ÅëÇÕÀ¸·Î ÀüÀå À¯Àüü ½ÃÄö½ÌÀÇ È¿À²¼º°ú È®À强ÀÌ Å©°Ô Çâ»óµÇ¾úÀ¸¸ç, AI ±â¹Ý ¾Ë°í¸®ÁòÀº ¹æ´ëÇÑ À¯Àüü µ¥ÀÌÅͼ¼Æ®¸¦ ºÐ¼®ÇÏ´Â µ¥ »ç¿ëµÇ¾î ´õ ³ôÀº Á¤È®µµ¿Í ¼Óµµ·Î Áúº´ ¸¶Ä¿¿Í À¯ÀüÀû µ¹¿¬º¯À̸¦ ½Äº°ÇÕ´Ï´Ù. ¶ÇÇÑ, ¸Ó½Å·¯´× ¸ðµ¨Àº À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏÀ» ±â¹ÝÀ¸·Î Áúº´ À§ÇèÀ» ¿¹ÃøÇÏ°í °³ÀÎÈ­µÈ Ä¡·á °èȹÀ» ÃßõÇϱâ À§ÇØ Àû¿ëµÇ°í ÀÖ½À´Ï´Ù. Ŭ¶ó¿ìµå ÄÄÇ»ÆÃÀº ´ë±Ô¸ð À¯Àüü µ¥ÀÌÅͼ¼Æ®ÀÇ ÀúÀå°ú °øÀ¯¸¦ ¿ëÀÌÇÏ°Ô Çϰí, ¿¬±¸ÀÚ¿Í ÀÇ·áÁøÀÌ ¼­·Î ´Ù¸¥ Àå¼Ò¿¡¼­ ½Ç½Ã°£À¸·Î Çù¾÷ÇÒ ¼ö ÀÖµµ·Ï Çß½À´Ï´Ù. ¶ÇÇÑ, ¾ÈÀüÇÑ À¯Àüü µ¥ÀÌÅÍ °ü¸®¸¦ À§ÇØ ºí·ÏüÀÎ ±â¼úÀÌ °ËÅäµÇ°í ÀÖÀ¸¸ç, ÇÁ¶óÀ̹ö½Ã¿Í À¯ÀüÀÚ Á¤º¸ÀÇ À±¸®Àû »ç¿ëÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù. °í󸮷® ½ÃÄö½Ì Ç÷§Æû°ú ÀÚµ¿È­µÈ »ý¹°Á¤º¸ÇÐ ÆÄÀÌÇÁ¶óÀÎÀÇ Ã¤ÅÃÀ¸·Î WGSÀÇ ¼Óµµ´Â ´õ¿í »¡¶óÁö°í ÀÖÀ¸¸ç, ÀÓ»ó°ú ¿¬±¸ ¸ðµÎ¿¡¼­ º¸´Ù Á¢±ÙÇϱ⠽±°í ºñ¿ë È¿À²ÀûÀÔ´Ï´Ù. AI¿Í ºòµ¥ÀÌÅÍ ºÐ¼®ÀÌ °è¼Ó ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ¿¡ µû¶ó ÀÇ·á ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿¡ Çõ¸íÀ» °¡Á®¿Ã WGSÀÇ °¡´É¼ºÀº °è¼Ó È®´ëµÇ°í ÀÖ½À´Ï´Ù.

ÀüÀå À¯Àüü ½ÃÄö½ÌÀÇ º¸±ÞÀ» °¡·Î¸·´Â °úÁ¦´Â ¹«¾ùÀϱî?

ÀüÀå À¯Àüü ½ÃÄö½ÌÀº ±× Çõ½ÅÀû ÀáÀç·Â¿¡µµ ºÒ±¸ÇÏ°í ºñ¿ë, µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã, À±¸®Àû ¹®Á¦ µîÀÇ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ½ÃÄö½Ì ºñ¿ëÀº ÃÖ±Ù ¸î ³â µ¿¾È Å©°Ô ³·¾ÆÁ³Áö¸¸, ƯÈ÷ ÀÚ¿øÀÌ ºÎÁ·ÇÑ ÀÇ·á ȯ°æ¿¡¼­´Â ÀÓ»ó¿¡¼­ ³Î¸® Ȱ¿ëµÇ±â¿¡´Â ¿©ÀüÈ÷ À庮À¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ´ë±Ô¸ð À¯Àüü µ¥ÀÌÅ͸¦ °ü¸®Çϰí ÇØ¼®Çϱâ À§Çؼ­´Â Àü¹®ÀûÀÎ Àü¹® Áö½Ä°ú °íµµÀÇ ÄÄÇ»ÆÃ ÀÎÇÁ¶ó°¡ ÇÊ¿äÇϸç, ¼Ò±Ô¸ð ¿¬±¸ ±â°üÀ̳ª ÀÇ·á ¼­ºñ½º Á¦°øÀÚ°¡ Á¢±ÙÇÒ ¼ö ÀÖ´Â ¹üÀ§°¡ Á¦ÇѵǾî ÀÖ½À´Ï´Ù. ¶ÇÇÑ, À¯Àüü Á¤º¸´Â ¸Å¿ì ¹Î°¨ÇÏ°í µ¿ÀÇ, µ¥ÀÌÅÍ ¼ÒÀ¯±Ç, ¾Ç¿ë °¡´É¼º¿¡ ´ëÇÑ À±¸®Àû ¹®Á¦°¡ ¹ß»ýÇϱ⠶§¹®¿¡ µ¥ÀÌÅÍ ÇÁ¶óÀ̹ö½Ã¿¡ ´ëÇÑ ¿ì·Áµµ Å« ¹®Á¦ÀÔ´Ï´Ù. ¶ÇÇÑ, À¯Àüü °Ë»ç ¹× µ¥ÀÌÅÍ °øÀ¯¿¡ ´ëÇÑ ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°¡ Áö¿ª¸¶´Ù ´Ù¸£±â ¶§¹®¿¡ ¼¼°è Ç¥ÁØÈ­¿¡ °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ °úÁ¦¸¦ ÇØ°áÇϱâ À§Çؼ­´Â ºñ¿ë Àý°¨ Àü·«¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ÅõÀÚ, µ¥ÀÌÅÍ º¸¾È ´ëÃ¥ °­È­, ±â¼ú Çõ½Å°ú ȯÀÚÀÇ ±Ç¸® ¹× ÇÁ¶óÀ̹ö½Ã »çÀÌÀÇ ±ÕÇüÀ» ¸ÂÃß´Â À±¸®Àû °¡À̵å¶óÀÎÀÇ °³¹ßÀÌ ÇÊ¿äÇÕ´Ï´Ù.

ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

ÀüÀå À¯Àüü ½ÃÄö½Ì ½ÃÀåÀÇ ¼ºÀåÀº ¸ÂÃãÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ½ÃÄö½Ì ±â¼úÀÇ ¹ßÀü, ¿¬±¸ ¹× Áø´Ü ºÐ¾ß¿¡¼­ÀÇ Àû¿ë È®´ë µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. Á¤¹ÐÀÇÇÐ ÀÌ´Ï¼ÅÆ¼ºêÀÇ ºÎ»óÀ¸·Î ÀÓ»ó ÇöÀå¿¡¼­ÀÇ WGS µµÀÔÀÌ °¡¼ÓÈ­µÇ¾î ¾Ï, À¯Àü¼º Áúȯ, °¨¿°¼º Áúȯ¿¡ ´ëÇÑ Ç¥Àû Ä¡·á°¡ °¡´ÉÇØÁ³½À´Ï´Ù. Â÷¼¼´ë ¹× 3¼¼´ë ½ÃÄö½Ì µî ½ÃÄö½Ì Ç÷§ÆûÀÇ Áö¼ÓÀûÀÎ °³¼±À¸·Î Á¤È®µµ, ¼Óµµ, °¡°ÝÀÌ Çâ»óµÇ¾î º¸´Ù ¸¹Àº ¿¬±¸ÀÚ¿Í ÀÓ»óÀǰ¡ WGS¸¦ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, ¼ÒºñÀÚ Á÷Á¢ À¯ÀüÀÚ °Ë»çÀÇ È®´ë´Â °³ÀÎ À¯ÀüüÇп¡ ´ëÇÑ °ü½ÉÀ» ºÒ·¯ÀÏÀ¸Å°°í Á¾ÇÕÀûÀÎ À¯ÀüÀÚ ºÐ¼®¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ³ó¾÷, »ý¸í°øÇÐ, ¸¶ÀÌÅ©·Î¹ÙÀÌ¿È ¿¬±¸¿¡ WGS°¡ ÅëÇյǸ鼭 ½ÃÀå ±âȸ´Â ´õ¿í ´Ù¾çÇØÁ³°í, À¯Àüü ½ÃÄö½ÌÀº °úÇÐÀû ¹ß°ß°ú ±â¼ú Çõ½ÅÀ» À§ÇÑ Áß¿äÇÑ µµ±¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù. Àü ¼¼°è À¯Àüü ¿¬±¸ ³ë·ÂÀÌ °­È­µÇ°í ÇコÄɾ µ¥ÀÌÅÍ ±â¹Ý ¸ÂÃãÇü Ä¡·á¹ýÀ¸·Î ÀüȯÇÔ¿¡ µû¶ó WGS ½ÃÀåÀº ÀÇ·á ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯ÁöÀÇ ¹Ì·¡¸¦ Çü¼ºÇϸç Å« ¼ºÀåÀ» ÀÌ·ê Áغñ°¡ µÇ¾î ÀÖ½À´Ï´Ù.

ºÎ¹®

±¸¼º¿ä¼Ò(Àåºñ, ¼Ò¸ðǰ, ¼­ºñ½º), À¯Çü(´ëÇü ÀüÀå À¯Àüü ½ÃÄö½Ì, ¼ÒÇü ÀüÀå À¯Àüü ½ÃÄö½Ì), ¿ëµµ(Àΰ£ ÀüÀå À¯Àüü ½ÃÄö½Ì, ½Ä¹° ÀüÀå À¯Àüü ½ÃÄö½Ì, µ¿¹° ÀüÀå À¯Àüü ½ÃÄö½Ì, ¹Ì»ý¹° ÀüÀå À¯Àüü ½ÃÄö½Ì), ÃÖÁ¾ ¿ëµµ(Çмú¡¤¿¬±¸±â°ü, º´¿ø¡¤Å¬¸®´Ð, Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

Global Industry Analysts´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â ÀϹÝÀûÀÎ LLM ¹× ¾÷°èº° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡°¡ ¼±º°ÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Whole Genome Sequencing Market to Reach US$5.8 Billion by 2030

The global market for Whole Genome Sequencing estimated at US$2.1 Billion in the year 2024, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 19.0% over the analysis period 2024-2030. Instruments, one of the segments analyzed in the report, is expected to record a 16.6% CAGR and reach US$2.8 Billion by the end of the analysis period. Growth in the Consumables segment is estimated at 22.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$560.3 Million While China is Forecast to Grow at 25.3% CAGR

The Whole Genome Sequencing market in the U.S. is estimated at US$560.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 25.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.4% and 16.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 15.8% CAGR.

Global Whole Genome Sequencing Market - Key Trends & Drivers Summarized

Why Is Whole Genome Sequencing Transforming the Field of Genomics?

Whole genome sequencing (WGS) has revolutionized genetic research, diagnostics, and personalized medicine by providing a comprehensive analysis of an individual’s entire genetic code. Unlike targeted sequencing methods that focus on specific genes, WGS examines all DNA sequences in an organism, enabling deeper insights into genetic variations, disease risks, and evolutionary traits. The increasing prevalence of genetic disorders, rare diseases, and cancer has driven demand for WGS in clinical diagnostics, as healthcare providers seek more accurate and personalized treatment approaches. Additionally, the field of pharmacogenomics is leveraging WGS to tailor drug prescriptions based on an individual’s genetic makeup, reducing adverse reactions and improving therapeutic efficacy. The growing use of genomic data in agriculture, microbiology, and forensic science has also expanded the scope of WGS applications. As sequencing costs continue to decline and computational tools for genome analysis improve, WGS is becoming a mainstream tool in medical and scientific research, paving the way for groundbreaking advancements in precision medicine.

How Are AI and Cloud Computing Enhancing Whole Genome Sequencing?

The integration of artificial intelligence (AI) and cloud computing has significantly enhanced the efficiency and scalability of whole genome sequencing. AI-driven algorithms are being used to analyze vast genomic datasets, identifying disease markers and genetic variations with greater accuracy and speed. Machine learning models are also being applied to predict disease risks and recommend personalized treatment plans based on genetic profiles. Cloud computing has facilitated the storage and sharing of large genomic datasets, enabling researchers and healthcare providers to collaborate in real time from different locations. Additionally, blockchain technology is being explored for secure genomic data management, ensuring privacy and ethical use of genetic information. The adoption of high-throughput sequencing platforms and automated bioinformatics pipelines has further accelerated the pace of WGS, making it more accessible and cost-effective for both clinical and research applications. As AI and big data analytics continue to evolve, the potential of WGS in revolutionizing medicine and biotechnology will only expand.

What Challenges Are Hindering the Widespread Adoption of Whole Genome Sequencing?

Despite its transformative potential, whole genome sequencing faces challenges related to cost, data privacy, and ethical concerns. While sequencing costs have dropped significantly in recent years, they remain a barrier for widespread clinical adoption, particularly in low-resource healthcare settings. The management and interpretation of large-scale genomic data require specialized expertise and advanced computational infrastructure, limiting accessibility for smaller research institutions and healthcare providers. Data privacy concerns also pose a major challenge, as genomic information is highly sensitive and raises ethical questions regarding consent, data ownership, and potential misuse. Additionally, regulatory frameworks governing genomic testing and data sharing vary across regions, creating hurdles for global standardization. Addressing these challenges requires continued investment in cost-reduction strategies, enhanced data security measures, and the development of ethical guidelines that balance innovation with patient rights and privacy.

What Factors Are Driving the Growth of the Whole Genome Sequencing Market?

The growth in the whole genome sequencing market is driven by several factors, including increasing demand for personalized medicine, advancements in sequencing technologies, and expanding applications in research and diagnostics. The rise of precision medicine initiatives has accelerated WGS adoption in clinical settings, enabling targeted therapies for cancer, genetic disorders, and infectious diseases. Continuous improvements in sequencing platforms, such as next-generation and third-generation sequencing, have enhanced accuracy, speed, and affordability, making WGS more accessible to a broader range of researchers and clinicians. Additionally, the expansion of direct-to-consumer genetic testing has fueled interest in personal genomics, driving demand for comprehensive genetic analysis. The integration of WGS in agriculture, biotechnology, and microbiome research has further diversified market opportunities, positioning genome sequencing as a key tool for scientific discovery and innovation. As global genomic research efforts intensify and healthcare moves toward data-driven personalized treatment approaches, the WGS market is poised for substantial growth, shaping the future of medicine and biotechnology.

SCOPE OF STUDY:

The report analyzes the Whole Genome Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Instruments, Consumables, Services); Type (Large Whole Genome Sequencing, Small Whole Genome Sequencing); Application (Human Whole Genome Sequencing, Plant Whole Genome Sequencing, Animal Whole Genome Sequencing, Microbial Whole Genome Sequencing); End-Use (Academic & Research Institutes, Hospitals & Clinics, Pharma & Biotech Companies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â